for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Alder Biopharmaceuticals Inc

ALDR.OQ

Latest Trade

18.66USD

Change

-0.05(-0.27%)

Volume

1,242,338

Today's Range

18.65

 - 

18.78

52 Week Range

8.39

 - 

18.90

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
18.71
Open
18.75
Volume
1,242,338
3M AVG Volume
40.14
Today's High
18.78
Today's Low
18.65
52 Week High
18.90
52 Week Low
8.39
Shares Out (MIL)
83.64
Market Cap (MIL)
1,564.85
Forward P/E
-4.69
Dividend (Yield %)
--

Next Event

Alder Biopharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Alder Biopharma Says If Co Terminates Lundbeck Deal To Enter Into A Superior Proposal, Co Will Be Required To Pay Termination Fee Of $87 Mln

Alder Biopharmaceuticals Reports Q2 2019 Results

Alder Biopharmaceuticals Q1 Loss Per Share $1.63

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Alder Biopharmaceuticals Inc

Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc.

Industry

Biotechnology & Drugs

Contact Info

11804 N Creek Pkwy S

+1.425.2052900

http://www.alderbio.com/

Executive Leadership

Robert W Azelby

President, Chief Executive Officer, Director

Carlos Campoy

Chief Financial Officer

Erin M Lavelle

Chief Operating Officer

James B. Bucher

Executive Vice President, General Counsel

Randal A. Hassler

Executive Vice President, Pharmaceutical Operations

Key Stats

2.47 mean rating - 15 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-3.230

2017

-4.950

2018

-4.870

2019(E)

-3.979
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
14.18
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
86.84
LT Debt To Equity (MRQ)
86.84
Return on Investment (TTM)
-68.19
Return on Equity (TTM)
-62.79

Latest News

Lundbeck buys Alder for $2 billion, eyes 'blockbuster' migraine therapy

Denmark's Lundbeck <LUN.CO> has agreed to buy Alder BioPharmaceuticals <ALDR.O> in a deal valued at almost $2 billion, hoping to reap profits from a potential blockbuster migraine drug.

Lundbeck to buy migraine treatment developer Alder BioPharmaceuticals

Danish pharmaceutical company Lundbeck will acquire Alder BioPharmaceuticals in a deal valued at almost $2 billion, the company said in a statement on Monday.

BRIEF-Alder Biopharmaceuticals Reports Q1 Loss Per Share Of $1.73

* ALDER BIOPHARMACEUTICALS® REPORTS FIRST QUARTER 2018 FINANCIAL AND OPERATING RESULTS

BRIEF-Alder Biopharmaceuticals Appoints Jeremy Green To Its Board Of Directors

* ALDER BIOPHARMACEUTICALS APPOINTS JEREMY GREEN TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-Alder Biopharmaceuticals - New Data Demonstrated Eptinezumab Increased Migraine-Free Intervals In Patients With Episodic Migraine

* ALDER BIOPHARMACEUTICALS® NEW DATA DEMONSTRATED EPTINEZUMAB INCREASED MIGRAINE-FREE INTERVALS (UP TO 32.5 DAYS) AND IMPROVED QUALITY-OF-LIFE OUTCOMES IN PATIENTS WITH EPISODIC MIGRAINE

BRIEF-Alder Biopharmaceuticals Presents New 12-Month Data Of Eptinezumab In Promise 1 Phase 3 Trial

* ALDER BIOPHARMACEUTICALS® PRESENTS NEW 12-MONTH DATA OF EPTINEZUMAB IN PROMISE 1 PHASE 3 TRIAL SHOWING LONG-TERM REDUCTION IN EPISODIC MIGRAINE

BRIEF-Alder Biopharmaceuticals Inc To Present New Phase 3 Migraine Prevention Data For Eptinezumab

* ALDER BIOPHARMACEUTICALS INC - TO PRESENT NEW PHASE 3 MIGRAINE PREVENTION DATA FOR EPTINEZUMAB AT 70TH ANNUAL AMERICAN ACADEMY OF NEUROLOGY MEETING Source text for Eikon: Further company coverage:

BRIEF-Alder Biopharmaceuticals Appoints Erin Lavelle To Newly Created Role Of Chief Operating Officer

* ALDER BIOPHARMACEUTICALS® APPOINTS ERIN LAVELLE TO NEWLY CREATED ROLE OF CHIEF OPERATING OFFICER Source text for Eikon: Further company coverage:

BRIEF-Redmile Group Reports 9.99 Pct Stake In Alder Biopharmaceuticals

* REDMILE GROUP, LLC REPORTS 9.99 PERCENT STAKE IN ALDER BIOPHARMACEUTICALS INC AS OF MARCH 23, 2018 - SEC FILING Source text: (https://bit.ly/2HZWQqw)

BRIEF-Alder Biopharma Q4 Loss Per Share $0.80

* ALDER BIOPHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL AND OPERATING RESULTS

BRIEF-Alder Biopharmaceuticals Enters Into European Patent Settlement, Global License Agreement With Teva

* ALDER BIOPHARMACEUTICALS® ENTERS INTO EUROPEAN PATENT SETTLEMENT AND GLOBAL LICENSE AGREEMENT WITH TEVA IN THE FIELD OF ANTI-CGRP-BASED THERAPY

BRIEF-Alder Announces $250 Million Committed Equity Financing

* ALDER BIOPHARMACEUTICALS INC - INVESTORS TO PURCHASE UP TO $250 MILLION OF NON-VOTING CLASS A PREFERRED STOCK DURING 3-YEAR TERM OF AGREEMENT

BRIEF-Alder Says Eptinezumab Met Primary Endpoint In Pivotal Phase 3 Promise 2 Clinical Trial

* ALDER ANNOUNCES EPTINEZUMAB SIGNIFICANTLY REDUCES MIGRAINE RISK MEETS PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN PIVOTAL PROMISE 2 PHASE 3 TRIAL FOR CHRONIC MIGRAINE PREVENTION

BRIEF-Alder Biopharmaceuticals Q3 loss per share $0.92

* Alder biopharmaceuticals announces third quarter 2017 financial and operating results

BRIEF-Alder Biopharmaceuticals Q2 loss per share $1.48

* Alder Biopharmaceuticals announces second quarter 2017 financial and operating results

BRIEF-Alder Biopharmaceuticals announces commencement of public offering of common stock

* Alder Biopharmaceuticals, Inc. announces commencement of public offering of common stock

Alder's shares tumble as migraine drug data disappoints

Alder BioPharmaceuticals Inc's late-stage study data on its experimental treatment to prevent episodic migraine fell short of investor expectations, sending its shares plunging as much as 26 percent to a more than two-and-half year low.

BRIEF-Alder Biopharmaceuticals announces positive eptinezumab phase 3 results

* Alder Biopharmaceuticals announces positive eptinezumab phase 3 results for prevention of frequent episodic migraine

Alder's migraine drug meets main goal in late-stage study

Alder BioPharmaceuticals Inc said on Tuesday its experimental treatment to prevent episodic migraine met the main goal of reducing monthly migraine days in a late-stage study.

BRIEF-Alder Biopharmaceuticals says presentation of positive data from Phase 2B clinical trial evaluating Eptinezumab for prevention of migraine

* Eptinezumab emerging clinical profile suggests migraine preventative benefit achieved as soon as 24-48 hours after single infusion

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up